Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission.
Adult
Aged
Aged, 80 and over
Dasatinib
/ pharmacology
Female
Follow-Up Studies
Humans
Killer Cells, Natural
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ blood
Lymphocyte Count
Male
Middle Aged
Prospective Studies
Protein Kinase Inhibitors
/ pharmacology
Remission Induction
/ methods
T-Lymphocytes, Cytotoxic
Treatment Outcome
CML
NK
TKI
dasatinib
stop
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
21
01
2020
revised:
31
05
2020
accepted:
01
06
2020
pubmed:
3
7
2020
medline:
15
12
2020
entrez:
3
7
2020
Statut:
ppublish
Résumé
This study presents the final report of the multicenter, prospective tyrosine kinase inhibitor discontinuation study, D-STOP, after a 3-year follow-up of 54 patients with chronic CML who discontinued dasatinib after a sustained deep molecular response (DMR) for ≥2 years with dasatinib treatment. Estimated treatment-free remission (TFR) rates at 12 and 36 months were 63.0% [95% confidence interval (CI): 48.7-74.3] and 59.3% (95% CI: 45.0-71.0), respectively. CD3
Identifiants
pubmed: 32614159
doi: 10.1111/cas.14518
pmc: PMC7419041
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Dasatinib
RBZ1571X5H
Banques de données
ClinicalTrials.gov
['NCT01627132']
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2923-2934Subventions
Organisme : the Epidemiological and Clinical Research Information Network (RCRIN)
Organisme : Bristol-Myers Squibb
Informations de copyright
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Blood. 2017 Feb 16;129(7):846-854
pubmed: 27932374
Blood. 2006 Jun 1;107(11):4532-9
pubmed: 16469872
Leuk Res. 2018 May;68:1-8
pubmed: 29494851
J Clin Oncol. 2017 Jan 20;35(3):298-305
pubmed: 28095277
Int J Clin Oncol. 2012 Dec;17(6):584-9
pubmed: 21986632
Cancer. 2016 May 1;122(9):1398-407
pubmed: 26998677
J Natl Cancer Inst. 2016 Mar 04;108(7):
pubmed: 26944912
J Clin Oncol. 2016 Aug 20;34(24):2851-7
pubmed: 27325849
Leukemia. 2017 May;31(5):1108-1116
pubmed: 27890936
Front Immunol. 2018 Oct 23;9:2433
pubmed: 30405627
Leukemia. 2010 Oct;24(10):1719-24
pubmed: 20811403
Lancet Haematol. 2015 Dec;2(12):e528-35
pubmed: 26686407
JAMA Oncol. 2016 May 1;2(5):625-632
pubmed: 26847662
Lancet Oncol. 2018 Jun;19(6):747-757
pubmed: 29735299
Int J Hematol. 2018 Feb;107(2):185-193
pubmed: 28929332
Cell Stem Cell. 2015 Mar 5;16(3):254-67
pubmed: 25748932
Haematologica. 2017 Aug;102(8):1368-1377
pubmed: 28522576
N Engl J Med. 2006 Dec 7;355(23):2408-17
pubmed: 17151364
Cancer Sci. 2020 Aug;111(8):2923-2934
pubmed: 32614159
Front Immunol. 2019 Jan 17;9:3152
pubmed: 30705677
Cancer Immunol Res. 2018 Jul;6(7):766-775
pubmed: 29784636
J Clin Oncol. 2009 Dec 10;27(35):6041-51
pubmed: 19884523
Leuk Res. 2018 Mar;66:66-72
pubmed: 29407585
Haematologica. 2016 Jun;101(6):717-23
pubmed: 26888022
Lancet Haematol. 2020 Mar;7(3):e218-e225
pubmed: 31978329
Cancer Sci. 2018 Jan;109(1):182-192
pubmed: 29058817
Int J Hematol. 2018 Dec;108(6):588-597
pubmed: 30151740
Lancet Oncol. 2010 Nov;11(11):1029-35
pubmed: 20965785
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Int J Hematol. 2014 Jan;99(1):41-52
pubmed: 24297450
Blood. 2010 Aug 5;116(5):772-82
pubmed: 20413659
Blood. 2017 Mar 2;129(9):1166-1176
pubmed: 28049640
J Exp Med. 2006 Jul 10;203(7):1701-11
pubmed: 16818678
J Clin Oncol. 2016 Jul 10;34(20):2333-40
pubmed: 27217448
Cell Stem Cell. 2013 Sep 5;13(3):285-99
pubmed: 23850243
Blood. 2009 May 7;113(19):4556-65
pubmed: 19246340
Crit Rev Oncol Hematol. 2014 Feb;89(2):242-7
pubmed: 24210599
Cancer Cell. 2013 Mar 18;23(3):347-61
pubmed: 23518349
Front Immunol. 2017 Apr 24;8:469
pubmed: 28484463
Am J Hematol. 2015 Sep;90(9):819-24
pubmed: 26103598